SeQuent Scientific and Viyash Life Sciences Secure Stock Exchange Approval for Merger Targeting Animal Health and API Integration

SeQuent Scientific Limited and Viyash Life Sciences have received approval from stock exchanges for their proposed merger. The process now moves forward with the filing of necessary documents with the National Company Law Tribunal (NCLT). This merger aims to consolidate two key business verticals: Global Animal Health and an integrated Active Pharmaceutical Ingredients (API) business.

The integration is expected to streamline operations across both companies, combining expertise in animal health solutions and API manufacturing. The approval from stock exchanges marks a significant step in the merger process, paving the way for regulatory review by NCLT. Further developments regarding this merger are anticipated as the legal proceedings progress.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 29, 2025

Author

Mark Chiang